NIKKEI 225
37,596.50 -31.98 (-0.08%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
83.85 +0.28 (+0.34%) GOLD FUTURES
2,340.90 -1.60 (-0.07%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,236.43 -438.79 (-0.85%)
Pharming Group N.V. (0QCO.IL)
| Previous close | 0.8963 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,144,457 |
| Market cap | 689.791M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswirePharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a un
GlobeNewswirePharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare Impact Awards h
ZacksPharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
